News coverage about Ocular Therapeutix (NASDAQ:OCUL) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.1984649642311 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Ocular Therapeutix (NASDAQ:OCUL) traded up $0.69 on Friday, reaching $5.60. 983,549 shares of the company’s stock were exchanged, compared to its average volume of 336,520. Ocular Therapeutix has a 12 month low of $3.30 and a 12 month high of $11.79. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39. The stock has a market cap of $162.72, a price-to-earnings ratio of -2.47 and a beta of 1.32.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54). Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The company had revenue of $523.00 million during the quarter, compared to analyst estimates of $0.52 million. During the same period last year, the firm posted ($0.39) EPS. Ocular Therapeutix’s revenue for the quarter was up 9.6% compared to the same quarter last year. equities research analysts anticipate that Ocular Therapeutix will post -2.37 EPS for the current fiscal year.
In other news, insider Antony C. Mattessich bought 21,000 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average cost of $4.29 per share, with a total value of $90,090.00. Following the acquisition, the insider now directly owns 21,000 shares in the company, valued at $90,090. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Amarpreet Sawhney bought 19,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $5.18 per share, with a total value of $98,420.00. Following the completion of the acquisition, the chairman now owns 696,390 shares in the company, valued at $3,607,300.20. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 69,500 shares of company stock valued at $304,781. Insiders own 26.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Ocular Therapeutix (OCUL) Receiving Somewhat Favorable Press Coverage, Report Shows” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/13/ocular-therapeutix-ocul-receiving-somewhat-favorable-press-coverage-report-shows.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.